<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Basiliximab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Basiliximab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Basiliximab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12526" href="/d/html/12526.html" rel="external">see "Basiliximab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12842" href="/d/html/12842.html" rel="external">see "Basiliximab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708643"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe basiliximab. The physician responsible for basiliximab administration should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped with adequate laboratory and supportive medical resources.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F139095"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Simulect</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866032"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Simulect</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F139126"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Immunosuppressant Agent;</li>
<li>
                        Interleukin-2 Inhibitor;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F139100"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bd77483-dc99-4408-b4c0-70ccd4313f39">Renal transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal transplantation (prophylaxis of acute rejection):</b> IV: 20 mg within 2 hours prior to transplant surgery, followed by a second 20 mg dose 4 days after transplantation (in combination with other immunosuppressants). The second dose should be withheld if complications occur (including severe hypersensitivity reactions or graft loss). Timing of basiliximab dosing may vary based on clinical and institutional factors; refer to institutional protocol for specific information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d284a69-533f-4b45-8749-a2815f735d02">Graft-versus-host disease, acute, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute (aGVHD), refractory (treatment) (off-label use):</b> IV: 20 mg on days 1 and 4; may repeat for recurrent acute GVHD (Schmidt-Hieber 2005). Additional data may be necessary to further define the role of basiliximab in this condition.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa4d1573-ae88-4e22-85fd-4b83639f479a">Heart transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplantation (prophylaxis of acute rejection) (off-label use):</b> IV: 20 mg on the day of transplant, followed by a second 20 mg dose on day 4 post-transplantation (in combination with other immunosuppressants) (Mehra 2005). The first dose is usually administered immediately prior to transplant or within the first hours postoperatively.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c9dde5a-3472-40b4-8491-0b0f38d67669">Liver transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver transplantation (prophylaxis of acute rejection) (off-label use): </b>IV: 20 mg on the day of transplant (day 0), followed by a second 20 mg dose on day 4 post-transplantation (in combination with other immunosuppressants) (Neuhaus 2002; Trunecka 2015). In clinical trials, the first dose was administered during the procedure once hemostasis was achieved or immediately post-transplant, or within 6 hours of organ reperfusion.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdb19e25-7519-4fdf-a0ef-8d40b51744e6">Lung transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung transplantation (prophylaxis of acute rejection) (off-label use</b>): IV: 20 mg prior to transplantation, followed by a second 20 mg dose 4 days after transplantation (in combination with other immunosuppressants) (Clinckart 2009; Swarup 2011). Additional trials may be necessary to further define the role of basiliximab in this condition.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990616"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50987784"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doe drugH1Div" id="F139101"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F139116"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12842" href="/d/html/12842.html" rel="external">see "Basiliximab: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution due to increased risk of hypersensitivity reactions. Hold second or subsequent dose(s) if severe hypersensitivity reactions or graft failure occurs.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa4d1573-ae88-4e22-85fd-4b83639f479a">Heart transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplantation:</b> Limited data available (ISHLT [Velleca 2023]):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose: IV: 10 mg administered immediately before cardiopulmonary bypass started is recommended, or may administer within 6 hours of organ perfusion (Ford 2005); reported timing of doses is variable; however, superior outcomes have been reported with pretransplant basiliximab administration (Grundy 2009).</p>
<p style="text-indent:-2em;margin-left:8em;">Second dose: IV: 10 mg administered 4 days after transplantation (Ford 2005).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose: IV: 20 mg administered immediately before cardiopulmonary bypass started is recommended, or may administer within 6 hours of organ perfusion (Ford 2005); reported timing of doses is variable; however, superior outcomes have been reported with pretransplant basiliximab administration (Grundy 2009).</p>
<p style="text-indent:-2em;margin-left:8em;">Second dose: IV: 20 mg administered 4 days after transplantation (Ford 2005).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c9dde5a-3472-40b4-8491-0b0f38d67669">Liver transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver transplantation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose: IV: 10 mg administered within 6 hours of organ perfusion (Cintorino 2006; Newland 2019; Spada 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">Second dose: IV: 10 mg administered 4 days after transplantation (Cintorino 2006; Newland 2019; Spada 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">Third dose (optional): IV: 10 mg has been repeated on postoperative days 8 to 10 if ascites fluid loss exceeds 70 mL/kg (Cintorino 2006; Spada 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose: IV: 20 mg administered within 6 hours of organ perfusion (Cintorino 2006; Newland 2019; Spada 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">Second dose: IV: 20 mg administered 4 days after transplantation (Cintorino 2006; Newland 2019; Spada 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">Third dose (optional): IV: 20 mg has been repeated on postoperative days 8 to 10 if ascites fluid loss exceeds 70 mL/kg or if total ascites volume ≥5 L (Cintorino 2006; Spada 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bd77483-dc99-4408-b4c0-70ccd4313f39">Renal transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal transplantation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose: IV: 10 mg administered within 2 hours prior to renal transplant surgery.</p>
<p style="text-indent:-2em;margin-left:8em;">Second dose: IV: 10 mg administered 4 days after transplantation.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose: IV: 20 mg administered within 2 hours prior to renal transplant surgery.</p>
<p style="text-indent:-2em;margin-left:8em;">Second dose: IV: 20 mg administered 4 days after transplantation.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073386"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073387"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F139069"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (exacerbation of hypertension: 3% to 10%), peripheral edema (leg edema: 3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hyperkalemia, hyperuricemia, hypokalemia, hypophosphatemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cytomegalovirus disease (11%), viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, insomnia, pain, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, upper respiratory infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal heart sounds (3% to 10%), angina pectoris (3% to 10%), atrial fibrillation (3% to 10%), cardiac arrhythmia (3% to 10%), chest pain (3% to 10%), dependent edema (3% to 10%), edema (3% to 10%), heart failure (3% to 10%), hypotension (3% to 10%), tachycardia (3% to 10%), thrombosis (3% to 10%), vascular disease (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (3% to 10%), hypertrichosis (3% to 10%), pruritus (3% to 10%), skin rash (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (3% to 10%), albuminuria (3% to 10%), dehydration (3% to 10%), diabetes mellitus (3% to 10%), hypercalcemia (3% to 10%), hyperlipidemia (3% to 10%), hypertriglyceridemia (3% to 10%), hypervolemia (3% to 10%), hypocalcemia (3% to 10%), hypoglycemia (3% to 10%), hypomagnesemia (3% to 10%), increased nonprotein nitrogen (3% to 10%), increased serum glucocorticoids (3% to 10%), weight gain (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis (3% to 10%), enlargement of abdomen (3% to 10%), esophagitis (3% to 10%), flatulence (3% to 10%), gastroenteritis (3% to 10%), gastrointestinal candidiasis (3% to 10%), gastrointestinal hemorrhage (3% to 10%), gingival hyperplasia (3% to 10%), hernia of abdominal cavity (3% to 10%), melena (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder dysfunction (3% to 10%), dysuria (3% to 10%), erectile dysfunction (3% to 10%), genital edema (male) (3% to 10%), hematuria (3% to 10%), oliguria (3% to 10%), ureteral disease (3% to 10%), urinary frequency (3% to 10%), urinary retention (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematoma (3% to 10%), hemorrhage (3% to 10%), hypoproteinemia (3% to 10%), leukopenia (3% to 10%), polycythemia (3% to 10%), purpuric disease (3% to 10%), thrombocytopenia (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including herpes simplex infection, herpes zoster infection) (3% to 10%), sepsis (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (3% to 10%), anxiety (3% to 10%), asthenia (3% to 10%), depression (3% to 10%), dizziness (3% to 10%), fatigue (3% to 10%), hypoesthesia (3% to 10%), malaise (3% to 10%), neuropathy (3% to 10%), paresthesia (3% to 10%), rigors (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3% to 10%), arthropathy (3% to 10%), back pain (3% to 10%), bone fracture (3% to 10%), lower leg pain (3% to 10%), muscle cramps (3% to 10%), myalgia (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (3% to 10%), conjunctivitis (3% to 10%), visual disturbance (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney impairment (including renal tubular necrosis) (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Abnormal breath sounds (3% to 10%), bronchitis (3% to 10%), bronchospasm (3% to 10%), cough (3% to 10%), pharyngitis (3% to 10%), pneumonia (3% to 10%), pulmonary edema (3% to 10%), rhinitis (3% to 10%), sinusitis (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Cyst (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome, hypersensitivity reaction (including anaphylaxis, severe hypersensitivity reaction)</p></div>
<div class="block coi drugH1Div" id="F139082"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to basiliximab or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F139066"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Severe hypersensitivity reactions, occurring within 24 hours, have been reported. Reactions, including anaphylaxis, have occurred both with the initial exposure and/or following re-exposure after several months; use caution during re-exposure to a subsequent course of therapy in a patient who has previously received basiliximab. Patients in whom concomitant immunosuppression was prematurely discontinued due to abandoned transplantation or early graft loss are at increased risk for developing a severe hypersensitivity reaction upon re-exposure. Discontinue permanently if a severe reaction occurs. Medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: In renal transplant recipients receiving basiliximab plus prednisone, cyclosporine, and mycophenolate, new-onset diabetes, glucose intolerance, and impaired fasting glucose were observed at rates significantly higher than observed in patients receiving prednisone, cyclosporine, and mycophenolate without basiliximab (Aasebo 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Human antimurine antibodies (HAMA): Treatment may result in the development of HAMA; however, limited evidence suggests the use of murine anti-lymphocytic antibody products is not precluded.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphoproliferative disorders: The incidence of lymphoproliferative disorders may be increased by immunosuppressive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Opportunistic infections: The incidence of opportunistic infections may be increased by immunosuppressive therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To be used as a component of an immunosuppressive regimen that may include a calcineurin inhibitor, adjunctive agent (eg, mycophenolate mofetil, everolimus), and corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppression therapy and organ transplant management.</b></p></div>
<div class="block foc drugH1Div" id="F139077"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simulect: 10 mg (1 ea); 20 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F139062"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323008"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Simulect Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4,006.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $5,258.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866033"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simulect: 20 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F139079"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For intravenous administration only. Infuse as a bolus or IV infusion over 20 to 30 minutes (bolus dosing is associated with nausea, vomiting, and local pain at the injection site); may be administered through either a peripheral or central line. For the treatment of acute GVHD (off-label use), the dose was administered over 30 minutes (Schmidt-Hieber 2005).</p></div>
<div class="block admp drugH1Div" id="F52612286"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only through central or peripheral access. Administer only after confirmation that patient will receive graft and immunosuppression. Reconstituted basiliximab solution may be administered undiluted as a bolus injection or further diluted and infused over 20 to 30 minutes. Bolus injection is associated with nausea, vomiting, and local pain at the injection site.</p></div>
<div class="block use drugH1Div" id="F139078"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Renal transplant (prophylaxis of acute rejection):</b> Prophylaxis of acute organ rejection in renal transplantation in combination with cyclosporine (modified) and corticosteroids.</p></div>
<div class="block off-label drugH1Div" id="F25721950"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute graft-versus-host disease, refractory (treatment); Heart transplant (prophylaxis of acute rejection); Liver transplant (prophylaxis of acute rejection); Lung transplant (prophylaxis of acute rejection)</p></div>
<div class="block mst drugH1Div" id="F25707942"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:6em;">Basiliximab may be confused with bezlotoxumab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298813"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F139071"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095574"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of childbearing potential should use effective contraceptive measures before beginning treatment, during, and for 4 months after completion of basiliximab treatment.</p></div>
<div class="block pri drugH1Div" id="F139083"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Basiliximab is a monoclonal IgG antibody which targets IL-2 receptors. IgG is known to cross the placenta; IL-2 receptors play an important role in the development of the immune system.</p>
<p style="text-indent:0em;margin-top:2em;">The Transplant Pregnancy Registry International (TPR) is a registry that follows pregnancies that occur in maternal transplant recipients or those fathered by male transplant recipients. The TPR encourages reporting of pregnancies following solid organ transplant by contacting them at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F139084"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if basiliximab is present in human milk. Because many immunoglobulins are secreted in milk and the potential for serious adverse reactions exists, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.</p></div>
<div class="block mop drugH1Div" id="F139075"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs and symptoms of acute rejection; hypersensitivity, infection</p></div>
<div class="block pha drugH1Div" id="F139065"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Basiliximab is a chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this receptor is expressed on activated T lymphocytes and is a critical pathway for activating cell-mediated allograft rejection</p></div>
<div class="block phk drugH1Div" id="F139081"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Mean: 36 days ± 14 days (determined by IL-2R alpha saturation in patients also on cyclosporine and corticosteroids).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Mean: V<sub>d</sub>: Children 1 to 11 years: 4.8 ± 2.1 L; Adolescents 12 to 16 years: 7.8 ± 5.1 L; Adults: 8.6 ± 4.1 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children 1 to 11 years: 9.5 ± 4.5 days; Adolescents 12 to 16 years: 9.1 ± 3.9 days; Adults: Mean: 7.2 ± 3.2 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 11 years: 17 ± 6 mL/hour; in pediatric liver transplant recipients, significant basiliximab loss through ascites fluid can increase total body clearance and reduce IL-2R (CD25) saturation duration; dosage adjustments may be necessary (Cintorino 2006; Kovarik 2002; Spada 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 12 to 16 years: 31 ±19 mL/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 41 ± 19 mL/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F139085"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Simulect</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19934089">
<a name="19934089"></a>Aasebø W, Midtvedt K, Valderhaug TG, et al. Impaired Glucose Homeostasis in Renal Transplant Recipients Receiving Basiliximab. <i>Nephrol Dial Transplant</i>. 2010;25(4):1289-1293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19934089/pubmed" id="19934089" target="_blank">19934089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31978255">
<a name="31978255"></a>Best LM, Leung J, Freeman SC, et al. Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. <i>Cochrane Database Syst Rev</i>. 2020;1(1):CD013203. doi:10.1002/14651858.CD013203.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/31978255/pubmed" id="31978255" target="_blank">31978255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17093248">
<a name="17093248"></a>Brennen DC, Daller JA, Lake KD, et al. Rabbit Antithymocyte Globulin Versus Basiliximab in Renal Transplantation. <i>N Engl J Med</i>. 2006;355(19):1967-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/17093248/pubmed" id="17093248" target="_blank">17093248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16757276">
<a name="16757276"></a>Cintorino D, Riva S, Spada M, et al. Corticosteroid-Free Immunosuppression in Pediatric Liver Transplantation: Safety and Efficacy After a Short-Term Follow-Up. <i>Transplant Proc</i>. 2006;38(4):1099-1100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16757276/pubmed" id="16757276" target="_blank">16757276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19328937">
<a name="19328937"></a>Clinckart F, Bulpa P, Jamart J, et al. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. <i>Transplant Proc</i>. 2009;41(2):607-609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19328937/pubmed" id="19328937" target="_blank">19328937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33016378">
<a name="33016378"></a>Diaz-Castrillon CE, Seese L, Mathier MA, et al. Nationwide variability in the use of induction immunosuppression for adult heart transplantation. <i>J Card Surg</i>. 2020;35(11):3053-3061. doi:10.1111/jocs.15075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/33016378/pubmed" id="33016378" target="_blank">33016378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143246">
<a name="16143246"></a>Ford KA, Cale CM, Rees PG, et al. Initial Data on Basiliximab in Critically Ill Children Undergoing Heart Transplantation. <i>J Heart Lung Transplant</i>. 2005;24(9):1284-1288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16143246/pubmed" id="16143246" target="_blank">16143246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26833657">
<a name="26833657"></a>Furuya Y, Jayarajian SN, Taghavi S, et al. The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients. <i>Am J Transplant</i>. 2016;16(8):2334-2341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/26833657/pubmed" id="26833657" target="_blank">26833657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19864164">
<a name="19864164"></a>Grundy N, Simmonds J, Dawkins H, et al. Pre-Implantation Basiliximab Reduces Incidence of Early Acute Rejection in Pediatric Heart Transplantation. <i>J Heart Lung Transplant</i>. 2009;28(12):1279-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19864164/pubmed" id="19864164" target="_blank">19864164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15968293">
<a name="15968293"></a>Ji SQ, Chen HR, Yan HM, et al. Anti-CD25 Monoclonal Antibody (Basiliximab) for Prevention of Graft-Versus-Host Disease After Haploidentical Bone Marrow Transplantation for Hematological Malignancies. <i>Bone Marrow Transplant</i>. 2005;36(4):349-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/15968293/pubmed" id="15968293" target="_blank">15968293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10075594">
<a name="10075594"></a>Kahan BD, Rajagopalan PR, Hall M. Reduction of the Occurrence of Acute Cellular Rejection Among Renal Allograft Recipients Treated With Basiliximab, a Chimeric Anti-Interleukin-2-Receptor Monoclonal Antibody. United States Simulect Renal Study Group. <i>Transplantation</i>. 1999;67(2):276-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/10075594/pubmed" id="10075594" target="_blank">10075594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12100507">
<a name="12100507"></a>Kovarik JM, Gridelli BG, Martin S, et al. Basiliximab in Pediatric Liver Transplantation: A Pharmacokinetic-Derived Dosing Algorithm. <i>Pediatr Transplant</i>. 2002;6(3):224-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/12100507/pubmed" id="12100507" target="_blank">12100507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30276862">
<a name="30276862"></a>Lange NW, Salerno DM, Sammons CM, Jesudian AB, Verna EC, Brown RS Jr. Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. <i>Clin Transplant</i>. 2018;32(12):e13415. doi:10.1111/ctr.13415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/30276862/pubmed" id="30276862" target="_blank">30276862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30655498">
<a name="30655498"></a>Lladó L, González-Castillo A, Fabregat J, et al. Efficacy and safety of delayed prolonged-release tacrolimus initiation in de novo hepatitis C virus-negative orthotopic liver transplant recipients: a single-center, single-arm, prospective study. <i>Ann Transplant</i>. 2019;24:36-44. doi:10.12659/AOT.912444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/30655498/pubmed" id="30655498" target="_blank">30655498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143248">
<a name="16143248"></a>Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. <i>J Heart Lung Transplant</i>. 2005;24(9):1297-1304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16143248/pubmed" id="16143248" target="_blank">16143248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34797576">
<a name="34797576"></a>Nanni AN, Harris M, Watson M, et al. Association of tacrolimus time-to-therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population. <i>Clin Transplant</i>. 2022;36(3):e14542. doi:10.1111/ctr.14542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/34797576/pubmed" id="34797576" target="_blank">34797576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9652559">
<a name="9652559"></a>Nashan B, Moore R, Amlot P, et al. Randomised Trial of Basiliximab Versus Placebo for Control of Acute Cellular Rejection in Renal Allograft Recipients. <i>Lancet</i>. 1997;350(9086):1193-1198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/9652559/pubmed" id="9652559" target="_blank">9652559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19120077">
<a name="19120077"></a>Neuberger JM, Mamelok RD, Neuhaus P, et al; ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. <i>Am J Transplant</i>. 2009;9(2):327-336. doi:10.1111/j.1600-6143.2008.02493.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19120077/pubmed" id="19120077" target="_blank">19120077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11862589">
<a name="11862589"></a>Neuhaus P, Clavien PA, Kittur D, et al. Improved Treatment Response With Basiliximab Immunoprophylaxis After Transplantation: Results From a Double-Blind Randomized Placebo-Controlled Trial. <i>Liver Transpl</i>. 2002;8(2):132-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/11862589/pubmed" id="11862589" target="_blank">11862589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31512802">
<a name="31512802"></a>Newland DM, Royston MJ, McDonald DR, et al. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients. <i>Pediatr Transplant</i>. 2019;23(8):e13573. doi:10.1111/petr.13573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/31512802/pubmed" id="31512802" target="_blank">31512802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24282128">
<a name="24282128"></a>Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA. Antibody induction therapy for lung transplant recipients. <i>Cochrane Database Syst Rev</i>. 2013;2013(11):CD008927. doi:10.1002/14651858.CD008927.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/24282128/pubmed" id="24282128" target="_blank">24282128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143252">
<a name="16143252"></a>Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. <i>J Heart Lung Transplant</i>. 2005;24(9):1327-1331. doi: 10.1016/j.healun.2004.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16143252/pubmed" id="16143252" target="_blank">16143252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16098072">
<a name="16098072"></a>Schmidt-Hieber M, Feitz T, Knauf W, et al. Efficacy if the Interleukin-2 Receptor Antagonist Basiliximab in Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Br J Haematol</i>. 2005;130(4):568-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16098072/pubmed" id="16098072" target="_blank">16098072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16770243">
<a name="16770243"></a>Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. <i>Transplantation</i>. 2006;81(11):1542-1548. doi:10.1097/01.tp.0000209924.00229.e5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16770243/pubmed" id="16770243" target="_blank">16770243</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Simulect (basiliximab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2020.</div>
</li>
<li>
<div class="reference">
                  Simulect (basiliximab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2019.</div>
</li>
<li>
<div class="reference">
                  Spada M, Petz W, Bertani A, et al. Randomized Trial of Basiliximab Induction Versus Steroid Therapy in Pediatric Liver Allograft Recipients Under Tacrolimus Immunosuppression. <i>Am J Transplant</i>. 2006;6(8):1913-1921.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21764603">
<a name="21764603"></a>Swarup R, Allenspach LL, Nemeh HW, et al. Timing of basiliximab induction and development of acute rejection in lung transplant patients. <i>J Heart Lung Transplant</i>. 2011;30(11):1228-1235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/21764603/pubmed" id="21764603" target="_blank">21764603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25707487">
<a name="25707487"></a>Trunecka P, Klempnauer J, Bechstein WO, et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens – the DIAMOND study. <i>Am J Transplant</i>. 2015;15(7):1843-1854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/25707487/pubmed" id="25707487" target="_blank">25707487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant.</i> 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33148937">
<a name="33148937"></a>Watanabe T, Yanase M, Seguchi O, et al. Influence of induction therapy using basiliximab with delayed tacrolimus administration in heart transplant recipients - comparison with standard tacrolimus-based triple immunosuppression. <i>Circ J</i>. 2020;84(12):2212-2223. doi:10.1253/circj.CJ-20-0164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/33148937/pubmed" id="33148937" target="_blank">33148937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14742976">
<a name="14742976"></a>Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. <i>Transplantation</i>. 2004;77(2):166-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/14742976/pubmed" id="14742976" target="_blank">14742976</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8803 Version 235.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
